GSK R&D chairman
Executive Summary
Senior VP-Worldwide Business Development & External Alliances in R&D Moncef Slaoui will succeed Tadataka Yamada as GlaxoSmithKline's R&D chairman. Yamada will resign from the post effective June 1 to serve as executive director of the Bill & Melinda Gates Foundation's Global Health Program. Yamada is credited with being the "principal architect" behind the transformation and improvement of the company's R&D engine. CEO J.P. Garnier recently touted GSK's pipeline as the largest in the pharmaceutical industry based on benchmark studies (1"The Pink Sheet" Sept. 26, 2005, p. 21)...